Mechanisms of regulation of compensatory platelet response in nephrolithiasis-associated hematuria in women with the follicular phase of the cycle

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. Evaluation of the severity of hematuria, the blood estradiol (Es) and progesterone (Pr) levels, the functional activity of platelet receptors and determination of the features of regulation of the platelet component of hemostasis in women with the follicular phase (FF) of the cycle.

Material and methods. The study included 59 women of reproductive age with nephrolithiasis, in whom hematuria was detected during examination. The blood Es and Pr levels were studied on the UniCel DxI 800 analyzer. The activity of purine P2Y- and PX1-receptors, TR-receptor, α2-adrenoreceptor, GPVI-receptor, PAF-receptor and adenosine A2A-receptor was analyzed. Receptor agonists were used in concentrations of EC50 and EC10. Platelet aggregation was assessed by the turbidimetric method on the ChronoLog analyzer. Statistical analysis was performed using the MedCalc package.

Results. In the examined contingent of women, the Es level was in the range of 164,3±5,0 pg/ml, and Pr – 0,44±0,04 ng/ml. The analysis of the platelet receptor apparatus revealed hyperreactivity of the PAF receptor and P2X1 receptor, normoreactivity of the purine P2Y receptors, A2A receptor and TR receptor, hyporeactivity of the GPVI receptor and α2-adrenoreceptor. The revealed dependence of hematuria on the Es level was associated with negative modulation of the signaling of the P2Y receptors, α2-adrenoreceptor and TR receptor. The compensatory platelet response was achieved due to the synergism of the P2Y receptors, P2X1 receptor and PAF receptor. The maximum effect of aggregation in vitro was reproduced during the interaction of purine P2Y receptors and P2X1 receptor, which was associated with an increase in the intracellular Ca2+ level of as a result of co-activation of signaling through Gq and Gi proteins and the opening of the ATP-dependent cation channel.

Conclusion. Understanding the mechanisms of modulation of compensatory platelet response in women with follicular phase of the cycle is necessary for the development of a strategy for personalized diagnostics and treatment of complications of nephrolithiasis.

全文:

受限制的访问

作者简介

Eduard Barinov

Donetsk State Medical University named after M. Gorky

编辑信件的主要联系方式.
Email: barinov.ef@gmail.com
ORCID iD: 0000-0002-8070-2242

Dr.Sci. (Med.), Professor, Head of the Department of Histology, Cytology, Embryology and Molecular Medicine

俄罗斯联邦, Donetsk

Sabina Akhundova

Donetsk State Medical University named after M. Gorky

Email: barkova.sabina@bk.ru
ORCID iD: 0009-0001-8400-6500

Senior Lecturer, Department of Histology, Cytology, Embryology and Molecular Medicine

俄罗斯联邦, Donetsk

参考

  1. Bargagli M., Scoglio M., Howles S.A. et al. Kidney stone disease: risk factors, pathophysiology and management. Nat. Rev. Nephrol. 2025, Aug 11. doi: 10.1038/s41581-025-00990-x.
  2. Berlin G., Hammar M., Tapper L. et al. Effects of age, gender and menstrual cycle on platelet function assessed by impedance aggregometry. Platelets. 2019;30(4):473–9. doi: 10.1080/09537104.2018.1466387.
  3. Ciccarese F., Brandi N., Corcioni B. et al. Complicated pyelonephritis associated with chronic renal stone disease. Radiol. Med. 2021;126(4):505–16. doi: 10.1007/s11547-020-01315-7.
  4. Ersöz G., Zergeroğlu A.M., Yakaryilmaz A. The effect of submaximal exercise on platelet aggregation during late follicular and midluteal phases in women. Thromb. Res. 2002;108(2–3):147–50. doi: 10.1016/s0049-3848(02)00404-8.
  5. Rocha G., Sierralta W., Valladares L. 27- Hydroxycholesterol reverses estradiol induced inhibition of platelet aggregation in postmenopausal women. Rev. Med. Chil. 2016;144(11):1377–81. doi: 10.4067/S0034-98872016001100002.
  6. Hashemzadeh M., Haseefa F., Peyton L. et al. The effects of estrogen and hormone replacement therapy on platelet activity: a review. Am. J. Blood Res. 2022;12(1):33–42. [PMID: 35291255].
  7. Geng H., Zhang H., Zhang W. et al. Transdermal 17-beta estradiol replacement therapy reduces megakaryocyte GPVI expression. Thromb. Res. 2008;123(1):93–9. doi: 10.1016/j.thromres.2008.03.014.
  8. Stépanian A., Fischer F., Flaujac C. et al. Light transmission aggregometry for platelet function testing: position paper on current recommendations and French proposals for accreditation. Platelets. 2024;35(1):2427745. doi: 10.1080/09537104.2024.2427745.
  9. Hashemzadeh M., Haseefa F., Peyton L. et al. The effects of estrogen and hormone replacement therapy on platelet activity: a review. Am. J. Blood Res. 2022;12(1):33–42. [PMID: 35291255].
  10. Choleva M., Antonopoulou S., Fragopoulou E. Winery By-Products In Vitro and In Vivo Effects on Atherothrombotic Markers: Focus on Platelet-Activating Factor. Front. Biosci. (Landmark Ed). 2025;30(1):25859. doi: 10.31083/FBL25859.
  11. Hechler B., Gachet C. Purinergic Receptors in Thrombosis and Inflammation. Arterioscler. Thromb. Vasc. Biol. 2015;35(11):2307–15. doi: 10.1161/ATVBAHA.115.303395.
  12. Jaiswal P., Kimmel A.R. Diverse Roles of the Multiple Phosphodiesterases in the Regulation of Cyclic Nucleotide Signaling in Dictyostelium. Cells. 2025;14(7):522. doi: 10.3390/cells14070522.
  13. Watala C., Wzorek J., Palma A. et al. A comparison of different regression models for the quantitative analysis of the combined effect of P2Y12 and P2Y1 receptor antagonists on ADP-induced platelet activation. Thromb. Res. 2022;211:88–97. doi: 10.1016/j.thromres.2022.01.024.
  14. Cassavaugh J., Longhi M.S., Robson S.C. Impact of Estrogen on Purinergic Signaling in Microvascular Disease. Int. J. Mol. Sci. 2025;26(5):2105. doi: 10.3390/ijms26052105.
  15. Shih C.C., Chan M.V., Kirkby N.S. et al. Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators. Br. J. Pharmacol. 2021;178(23):4758–71. doi: 10.1111/bph.15659.
  16. Li Y., Wang W., Cai J. et al. Selective Inhibition of P2Y1 and P2Y12 Receptor Signal Pathways in Platelet Aggregation in Transgenic Cell Lines and Rats by Potassium 2-(1-Hydroxypentyl)-Benzoate, Puerarin and Salvianolic Acid B. CNS. Neurosci. Ther. 2024;30(11):e70089. doi: 10.1111/cns.70089.

补充文件

附件文件
动作
1. JATS XML
下载